LYNPARZA (olaparib)

LynparzaTM (olaparib) is a first‐in‐class PARP inhibitor (PARPi) that allows women with BRCA mutated (BRCAm) platinum‐sensitive relapsed high-grade serous ovarian cancer to extend progression‐free survival (PFS).1-3

About LYNPARZA

Lynparza marketing image. “I have ovarian cancer. TEST ME for BRCAm. TREAT ME with Lynparza.”
Lynparza marketing image. “I have ovarian cancer. TEST ME for BRCAm. TREAT ME with Lynparza.”

Until Lynparza, ovarian cancer treatment has been limited, with no specific treatment for patients who have a BRCAm.13

Lynparza is a first‐in‐class PARP inhibitor (PARPi) that allows women with BRCA mutated (BRCAm) platinum‐sensitive relapsed ovarian cancer to extend progression‐free survival (PFS).1-3

*LynparzaTM (olaparib) is indicated as monotherapy for the maintenance treatment of adult patients with platinum‑sensitive relapsed BRCA‑mutated (germline and/or somatic) high-grade serous epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in response (complete response or partial response) to platinum-based chemotherapy.4

Mechanism of Action

Lynparza, a first-in-class PARPi, is the first molecular biomarker-driven targeted treatment in BRCAm platinum-sensitive relapsed ovarian cancer.1-3

       

Are you familiar with PARP inhibitor (PARPi)?

  • Every day thousands of DNA lesions occur in cells, including single strand breaks (SSBs).28
  • The enzyme poly-ADP ribose polymerase (PARP) is a key protein required for the efficient repair of these SSBs through a mechanism known as base excision repair (BER).29,30
  • When PARP function is inhibited, cells cannot effectively repair SSBs. As a result, these unrepaired SSBs are converted to double strand breaks (DSBs) during DNA replication, requiring repair via the homologous recombination pathway (HRR).31,32
Image showing the Inhibition of the PARP function
Image showing the Inhibition of the PARP function

DNA Repair

PARPi selectively induce cell death in BRCAm cancer cells vs normal cells33

  • BRCA1 and BRCA2 are human genes that play a central role in repairing DNA DSBs via the homologous recombination pathway. When either gene is mutated, DNA DSBs may not be repaired properly. 34
  • Non-tumour cells have at least one functional copy of BRCA and are able to repair DNA via HRR. However, BRCAm tumour cells have lost both copies of BRCA and cannot repair DSBs through HRR. 34
  • Lynparza, by inhibiting the function of PARP, in combination with the BRCA mutation (absence of functional BRCA 1/2), selectively induces cancer cell death. 4, 33
Image showing the Lynparza effect on the Inhibition of the PARP function in combination with the BRCA mutation.
Image showing the Lynparza effect on the Inhibition of the PARP function in combination with the BRCA mutation.